C-Path Awarded FDA Drug Development Tool Research Grant to Develop a Qualification Plan for the Symptoms of Major Depressive Disorder Momentary Assessment (SMDDMA) C-Path’s Patient-Reported Outcome (PRO) Consortium announced that it has been awarded a U.S. Food and Drug Administration (FDA)
C-Path Launches Consortium to Accelerate Medical Product Development in Sickle Cell Disease September is National Sickle Cell Awareness Month TUCSON, Ariz., Sept. 17, 2020 — The Critical Path Institute (C-Path) today
October 28, 2021-October 29, 2021 View Now | October 28-29 | International Neonatal Consortium 2020 Virtual Workshop This two-day virtual workshop, hosted in collaboration with EMA, will bring together hundreds of INC consortia members and collabo
October 10, 2020 Watch Now: Accelerating Drug Development for Rare Diseases through Data Sharing and Analysis Webinar Despite increasing numbers of drug targets and technologies, rare disease drug development is frequently slowed by t
September 13, 2020 How Math, Statistics, and Artificial Intelligence Can be Used to Develop Treatments for Major Diseases: Quantitative Medicine at the Critical Path Institute This presentation focuses on the bridge between a person’s ultimate health in light of being affected by a debilitating disease,
September 13, 2020 New Uses for Existing Drugs: Applications for COVID-19 and Valley Fever What is drug repurposing and why is it important? Learn more about the CURE ID web-based app made possible by the National Center
September 13, 2020 Drug Development and Regulation in the Age of Precision Medicine An introduction and overview of the Critical Path Institute and University of Arizona collaboration and the regulatory sci
